Name

Acupath Laboratories

Legal name

Acupath Laboratories, Inc.

Website

https://acupath.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Plainview

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Laboratory Testing Services: Anatomic pathology testing services billed to insurance companies, Medicare, Medicaid, and directly to clients. Services include surgical pathology, FISH testing, molecular diagnostics, flow cytometry, and specialized cancer biomarker tests (URO17). Pricing varies by test type and billing model (TC only, PC only, or Global).
2. TC/PC Services Partnership Model: Technical Component only (TC) or Professional Component only (PC) services offered to physician offices and pathology practices. With over 100 active TC/PC customers, Acupath is one of the largest providers nationwide. Maximizes financial and clinical benefits for practice pathology specimens.
3. Histology Lab Development: Consulting and implementation services to help physician practices establish on-site histology labs, including required applications, licensure, contracting, credentialing, and reimbursement collection.
4. Direct/Client Billing: Aggressive pricing offered on all tests on both TC only and Global basis, where permissible by federal and state law.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Acupath Laboratories is a sub-specialized anatomic and molecular pathology laboratory providing diagnostic testing services including surgical pathology, FISH (Fluorescence In Situ Hybridization) genetic panels, molecular PCR infectious disease panels, flow cytometry/hematopathology, and proprietary cancer biomarker tests such as Acu-URO17 for bladder cancer. The lab serves physician offices, hospitals, NYS Article 28 ASCs, and commercial laboratories nationwide through multiple business models including TC/PC partnerships, direct/client billing, and histology lab development consulting, with 24-72 hour turnaround times on most tests.

Product overview

Acupath Laboratories is a nationwide provider of sub-specialized anatomic and molecular pathology services offering a comprehensive portfolio of diagnostic products and testing services. The core offerings include AI-powered diagnostic tools (Acu-URO17 bladder cancer biomarker, ArteraAI Prostate Test, Vesta), digital pathology (Lumea+ platform), molecular PCR infectious disease panels (GI, UTI, Wound, Respiratory), FISH testing (AcuProbe panels for melanoma, prostate, bladder, esophageal cancer), flow cytometry/hematopathology, and traditional surgical pathology with extensive immunohistochemistry. The company operates TC/PC partnership models for physician practices and provides web-based reporting through AcuReview 2.0. Founded in 1998 and based in Plainview, NY, with over 250,000 specimens processed annually and 700+ active clients.

Differentiator

Problem solved

Functional benefit

Brands

• ACU-URO17: FDA-recognized Breakthrough Device for bladder cancer biomarker detection using Keratin 17 (K17) antibody. Clinically proven for over 5 years with 99% NPV and 96% sensitivity for ruling in/out bladder cancer.
• Acu-UTI
• BioFire GI Panel
• COVID-19/Flu/RSV Testing

Products and services

• Acu-URO17 Bladder Cancer Biomarker Test FDA-recognized Breakthrough Device bladder cancer biomarker test that detects cytokeratin 17 (K17) expression in urine samples, used in conjunction with urine cytology and/or FISH to improve diagnosis and management of bladder cancer. Offers 99% NPV for ruling out and 96% sensitivity for detecting both low and high-grade urothelial carcinoma. Priced at $119 (CMS rate).
• ArteraAI Prostate Test AI-powered prostate cancer risk stratification tool that analyzes digital pathology images of prostate biopsies to predict therapy benefit and forecast long-term outcomes in localized prostate cancer. The only tool in NCCN Clinical Practice Guidelines for both predictive functions, delivering results within 24 hours.
• Vesta AI Diagnostic Test AI-powered diagnostic test for non-muscle invasive bladder cancer delivered through partnership with Valar Labs, providing advanced diagnostic solutions for improved bladder cancer management.
• AcuProbe FISH Panels Proprietary fluorescence in situ hybridization panels including UroVysion (bladder cancer detection with 97% sensitivity), PTEN ERG (prostate cancer), Barrett's Esophagus FISH, TERC FISH, PathVysion HER2/neu, and Melanoma FISH for genetic abnormality detection in solid tumors.
• Acu-UTI Molecular PCR Test Molecular RT-PCR testing for urinary tract infections detecting 31 organisms and 26 resistance genes. NYSDOH approved, approximately 25% more sensitive than culture alone with 24-48 hour turnaround.
• Gastrointestinal Pathogen Panel (BioFire GI) BioFire FilmArray PCR-based molecular infectious disease test detecting 22 pathogens simultaneously from stool samples with 98.5% sensitivity and 99.2% specificity. Detects 25%-36% more pathogens than traditional GI testing with ~1 hour run time.
• RSV, Flu A & Flu B PCR PCR-based respiratory virus testing differentiating between RSV, Influenza A, and Influenza B from nasopharyngeal swabs with results within 24 hours.
• Wound Pathogen Panel rt-PCR wound infection testing using 43 array-based assays to detect bacteria, fungi, and antibiotic resistance genes with results within 48 hours.
• Nail Pathogen Panel rt-PCR testing detecting 16 pathogens from nail samples within 24-48 hours, 3.5 times more sensitive than traditional culture techniques with 98-100% pathogen certainty.
• Flow Cytometry and Hematopathology Immunophenotyping services using BD FACS Canto 10-color flow cytometry for diagnosis of chronic or acute B-cell, T-cell, Myeloid, or Plasma Cell Neoplasms with comprehensive 31 marker panels.
• Surgical Pathology Fine needle aspirations, surgical excisions, margin assessments, sentinel lymph node analysis, and sentinel node micrometastasis detection with ER/PR, Her2/neu, and MIB-1 (KI-67) testing.
• Special Stains & Antibody Markers Extensive immunohistochemistry panel including over 150 antibody markers for diagnostic and prognostic assessment across multiple tissue types and cancer applications.
• Dermatopathology Board-certified dermatopathologist interpretation of skin and soft tissue biopsies using shave, punch, or excision procedures with direct immunofluorescence, genetic FISH testing, and molecular T-cell gene rearrangement studies.
• Gastroenterology Pathology Expert interpretation of endoscopic biopsies and surgical specimens for upper and lower GI tracts with cytology, FISH, and specialized stains for H. pylori, HPV, and various GI markers.
• Uropathology Expert prostate, bladder, testis, and vas deferens biopsy interpretation with UroVysion, PTEN/ERG, and TERC FISH testing along with PSA testing and stone analysis.
• TC/PC Services Partnership Model Technical Component only (TC) or Professional Component only (PC) services offered to physician offices and pathology practices. With over 100 active TC/PC customers, Acupath is one of the largest providers of TC-only services nationwide, providing revenue-generating partnerships for physician practices.
• Histology Lab Development Consulting Consulting and implementation services to help physician practices establish on-site histology labs, including required applications, licensure, contracting, credentialing, and reimbursement collection. Includes NYS Article 28 ASC and CLEP certification guidance.

Quantifiable outcome

• 97% sensitivity for bladder cancer detection with UroVysion FISH
• +7 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability8 records

Feature6 records

Partnerships

Five partnerships are on record, tiered core and flagship.

• ArteraAIcoreTechnology or Integration · 28 May 2026Acupath integrated the ArteraAI Prostate Test into its digital pathology diagnostic pathway, becoming the first pathology lab in New York to offer this AI-powered tool for localized prostate cancer. The test analyzes digital pathology images and delivers results within 24 hours, predicting therapy benefit and forecasting long-term outcomes.
• Azer ScientificflagshipTechnology or Integration · 27 February 2026Acupath partnered with Azer Scientific to install the first AzerView LH510 Digital Pathology Scanner in the United States. This marks a significant milestone for digital pathology and diagnostic innovation, enabling enhanced digital pathology workflow capabilities.
• Valar LabscoreStrategic or Co-development Partner · 3 December 2025Strategic partnership to deliver Vesta, an AI-powered diagnostic test for non-muscle invasive bladder cancer. The partnership aims to provide advanced diagnostic solutions for improved bladder cancer management.
• LumeacoreTechnology or Integration · 20 March 2025Lumea is the U.S. leader in primary clinical digital pathology. Acupath partnered with Lumea to adopt the Lumea+ Viewer and digital pathology platform, enabling seamless transition from traditional to digital pathology with improved biopsy handling, tracking, workflow, and diagnosis. The partnership also includes AI-powered quantification of the URO17 bladder cancer biomarker through AIRA Matrix's algorithms.
• AIRA Matrix Private LimitedcoreTechnology or Integration · 20 March 2025AIRA Matrix delivers AI-based diagnostic, prognostic, and predictive applications in cancer care. The partnership with Acupath and Lumea focuses on developing algorithms that automate quantification of the URO17 test, improving accuracy and turnaround time for bladder cancer diagnosis. The collaboration enhances pathologists' ability to make accurate diagnoses and improve treatment decisions.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Quest Diagnostics: National clinical laboratory incumbent with anatomic pathology, molecular, and infectious disease testing. COO Brian Kunkel's prior employer; competes with Acupath across virtually all test categories but operates at national scale with broad payor access.
• Foundation Medicine: Genomic profiling company owned by Roche providing comprehensive genomic testing in oncology. Listed as an Acupath vendor partner; competes indirectly on molecular oncology and companion diagnostics.
• Laboratory Corporation of America (LabCorp): Largest U.S. clinical laboratory network including anatomic pathology through Dianon and integrated oncology services. Competes with Acupath on routine anatomic pathology and increasingly on molecular oncology and companion diagnostics.
• Dianon Pathology (LabCorp): Anatomic pathology subsidiary of LabCorp providing sub-specialized surgical pathology. CSO John Cucci's prior employer; competes directly with Acupath in physician-office anatomic pathology but at vastly larger scale under the LabCorp umbrella.

Regional players

• Sonic Healthcare USA: International pathology operator with U.S. presence (e.g., ProPath, Aurora Diagnostics) offering sub-specialized anatomic pathology. Comparable in sub-specialty focus and TC/PC-style service models but with global scale.

Emerging players

• Guardant Health: Liquid biopsy and precision oncology company. Listed as an Acupath vendor partner; represents an emerging technology paradigm that may eventually compete with or complement tissue-based pathology workflows.
• Caris Life Sciences: Molecular profiling company with MI Profile and ADAPT AI platforms in oncology. Listed as a vendor partner of Acupath, indicating overlap in molecular oncology testing with an AI-driven differentiation strategy comparable to Acupath's ArteraAI and Vesta integrations.
• P4 Diagnostix (formerly Theranostix): Specialized molecular and FISH diagnostics laboratory serving community urologists and gastroenterologists. Highly comparable to Acupath's TC/PC and specialty FISH test offering, with overlapping urology and GI physician customer base.

Direct peers

• NeoGenomics: Oncology-focused clinical laboratory providing anatomic pathology, FISH, molecular, and flow cytometry services. Direct competitor in urologic and GI oncology diagnostics with overlapping FISH and molecular test menu.
• Miraca Life Sciences (now Inform Diagnostics): Specialized anatomic pathology laboratory offering sub-specialty reads across multiple organ systems. Closely comparable to Acupath in test menu, sub-specialty focus, and TC/PC service model serving community physician practices.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/AcupathLabs
• Facebookfacebook.com/Acupath-168463949835762
• LinkedInlinkedin.com/company/acupathlaboratoriesinc.

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acupath Laboratories